Cargando…
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
BACKGROUND: Poor control of type 2 diabetes results in substantial long-term consequences. Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both added to glimepi...
Autores principales: | Sullivan, Sean D, Alfonso-Cristancho, Rafael, Conner, Chris, Hammer, Mette, Blonde, Lawrence |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667489/ https://www.ncbi.nlm.nih.gov/pubmed/19245711 http://dx.doi.org/10.1186/1475-2840-8-12 |
Ejemplares similares
-
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021) -
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
por: Bode, B W, et al.
Publicado: (2010) -
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009) -
Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma
por: El-Enany, Nahed M, et al.
Publicado: (2012) -
Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
por: Rao, Ravi Prakash, et al.
Publicado: (2011)